New drug tested in kids with rare Muscle-Weakening disease
NCT ID NCT06987539
Summary
This study aims to understand how a drug called inebilizumab works in children and teenagers with generalized myasthenia gravis (gMG), a rare autoimmune disease that causes severe muscle weakness. It will enroll 15 participants aged 2 to 18 years old to measure the drug's levels in the body and check its safety. The goal is to see if this treatment can help control the disease in younger patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Neuromuscular Center
RECRUITINGAustin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.